SOURCE-LINKED STUDY SUMMARY
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Abstract summarized · Quality not appraised
- Studied
- Randomized trial testing semaglutide versus placebo, both alongside lifestyle intervention, over 68 weeks.
- Who / model
- 1961 adults with overweight or obesity and no diabetes.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- Found
- The two main outcomes favored semaglutide: average weight fell 14.9% versus 2.4%, and 86.4% versus 31.5% lost at least 5%. Nausea and diarrhea were common. Digestive side effects caused treatment withdrawal in 4.5% versus 0.8%.
- Limits
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Research findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2032183